Why Am I Not Losing Weight on Retatrutide? Understanding the Possible Reasons

Retatrutide has generated substantial interest due to its remarkable clinical outcomes, with Phase 3 data showing average weight loss up to 70 pounds (28.3%) over 80 weeks. Some participants even achieved weight loss approaching 30% after 104 weeks. However, individual results vary—and for some, the scale may not move as expected. Understanding the possible reasons is the first step toward addressing the issue.

Not Everyone Responds the Same Way

Clinical trial data reveal that weight loss with retatrutide is heterogeneous. Subgroup analyses from Phase 2 trials identified clear demographic patterns: women experienced greater mean weight loss than men (up to 28.5% versus 21.9% in one analysis), younger adults lost more weight than those over 50, and individuals with a higher baseline BMI (≥35 kg/m²) achieved greater percentage weight reduction than those with lower starting BMIs. These variations don't mean the drug "isn't working"—rather, they reflect biological differences in how individuals metabolise the medication's triple-hormone mechanism targeting GLP-1, GIP, and glucagon receptors.

The Dose Escalation Phase Requires Patience

Retatrutide is administered with gradual dose escalation. The Phase 3 TRIUMPH-1 trial protocol started participants at 2 mg weekly, increasing every 4 weeks to target doses of 4 mg, 9 mg, or 12 mg . If you are in the early weeks or at a lower maintenance dose, significant weight loss may not yet be apparent. Phase 2 data demonstrated dose-dependent efficacy—participants on 1 mg lost less than 10% of body weight, whereas the 4-8-12 mg group achieved nearly 24%. Lower doses still deliver clinically meaningful results but require more time to accumulate.

Lifestyle Factors Still Matter

While retatrutide reduces appetite and increases energy expenditure through glucagon receptor agonism, it does not eliminate the impact of lifestyle choices. Dietary quality, physical activity, sleep, and stress management remain critical. Consuming calorie-dense foods, ultra-processed items, sugary drinks, or alcohol can offset the caloric deficit the medication helps create. Chronic stress elevates cortisol, promoting fat storage, while poor sleep increases hunger hormones that may undermine appetite suppression. Even with triple-agonist therapy, medication is most effective as part of a comprehensive approach involving dietary modification and regular movement.

Medical Conditions and Medications Can Blunt Weight Loss

Several underlying medical conditions can impair weight loss even when effective medication is used. Hypothyroidism reduces metabolic rate; polycystic ovary syndrome (PCOS) is associated with insulin resistance that hinders fat loss, and Cushing's syndrome promotes fat accumulation. Additionally, medications including certain antidepressants (mirtazapine, amitriptyline), antipsychotics, corticosteroids, insulin, and sulfonylureas can promote weight gain or impede progress. Addressing these underlying factors may be essential before concluding that retatrutide is ineffective.

The Unique Mechanism May Take Time

Retatrutide's glucagon receptor component differentiates it from other incretin therapies by increasing energy expenditure and fatty acid oxidation, not simply suppressing appetite. This metabolic shift may produce a different weight-loss trajectory than GLP-1-only or dual agonists. Importantly, Phase 3 data showed no weight-loss plateau through 80 weeks, suggesting that the medication's effects continue accumulating over time. If you are in the earlier stages of treatment or at a lower dose, patience is warranted.

What to Do If You're Not Seeing Results

1. Review your dose and timeline—confirm you have progressed through appropriate dose escalation.

2. Audit lifestyle factors—diet quality, physical activity, sleep, and stress management should be optimised alongside treatment.

3. Consider underlying medical conditions—hypothyroidism, PCOS, or medications that may be counteracting progress.

4. Discuss with your trial team or prescriber—they can help identify and address specific barriers.

Important: Retatrutide remains an investigational drug not approved by any regulatory body. Legitimate access is limited to participation in clinical trials. Products sold outside this framework are unapproved, unverified, and potentially unsafe.